FilingReader Intelligence
Mankind Pharma reports 25% revenue growth despite profit drop
August 6, 2025 at 06:09 PM UTC•By FilingReader AI
Mankind Pharma reported revenue growth of 25% year-on-year to INR 3,570 crores in Q1 FY26, with EBITDA margin at 23.8%.
Domestic revenue increased 19% driven by volume recovery and chronic segment outperformance. International business revenue surged 81% to INR 469 crore, including BSV consolidation benefits.
However, net profit after tax decreased 17.4% to INR 445 crores, impacted by higher finance and depreciation costs from the BSV consolidation.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:MANKIND•Bombay Stock Exchange
News Alerts
Get instant email alerts when Mankind Pharma publishes news
Free account required • Unsubscribe anytime